CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designe...
Phase 2
Baltimore, Maryland, United States and 33 other locations
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia...
Phase 4
Baltimore, Maryland, United States and 50 other locations
or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic...
Phase 3
Bethesda, Maryland, United States and 98 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Washington D.C., District of Columbia, United States and 204 other locations
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; par...
Phase 3
Bethesda, Maryland, United States and 147 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Northwest WA, Wisconsin, United States and 130 other locations
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic ...
Phase 2
Bethesda, Maryland, United States and 134 other locations
Epcoritamab will be tested either inRelapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as:* Monotherapy, or* Com...
Phase 1, Phase 2
Bethesda, Maryland, United States of America and 82 other locations
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic...
Phase 3
York, Pennsylvania, United States and 193 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Washington D.C., District of Columbia, United States and 83 other locations
Clinical trials
Research sites
Resources
Legal